JFG
CCCC icon

Jefferies Financial Group’s C4 Therapeutics CCCC Stock Holding History

Jefferies Financial Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.7K Sell
26,120
-9,220
-26% -$21.7K ﹤0.01% 1630
2025
Q4 		$67.5K Sell
35,340
-2,860
-7% -$6.78K ﹤0.01% 1744
2025
Q3 		$84.8K Buy
+38,200
New +$91.7K ﹤0.01% 1356

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Financial Group's CCCC Position: Q1 2026 in Review

Jefferies Financial Group reduced its C4 Therapeutics (CCCC) stake by 26% in Q1 2026, selling an estimated $21.7K and leaving 26,120 shares worth $68.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1630.

Jefferies Financial Group first reported a position in CCCC in Q3 2025 and has held it in 3 quarters since. The position peaked at $84.8K in Q3 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Jefferies Financial Group held 26,120 shares of C4 Therapeutics worth $68.7K as of Q1 2026.
  • Jefferies Financial Group sold 9,220 C4 Therapeutics shares in Q1 2026, an estimated $21.7K.
  • C4 Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1630 holding.
  • Jefferies Financial Group first reported a position in C4 Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jefferies Financial Group's C4 Therapeutics position peaked at $84.8K in Q3 2025.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.